Compile Data Set for Download or QSAR
Report error Found 150 Enz. Inhib. hit(s) with all data for entry = 3353
TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397684BDBM397684(US9994547, Example 53 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 2.51nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397657BDBM397657(US9994547, Example 26 | (R)-N-(5-(4-cyano-3-((1-(d...)
Affinity DataIC50: 3.16nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397717BDBM397717(US9994547, Example 86 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 3.98nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397772BDBM397772(US9994547, Example 141 | (R)-N-(5-(6-cyano-5-((2-(...)
Affinity DataIC50: 5.01nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397665BDBM397665(US9994547, Example 34 | (S)-N-(5-(4-cyano-3-((1-(d...)
Affinity DataIC50: 6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397679BDBM397679(US9994547, Example 48 | (R)-N-(5-(6-cyano-5-((2-ox...)
Affinity DataIC50: 6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397638BDBM397638(US9994547, Example 7 | (S)-N-(5-(4-cyano-3-((1-(di...)
Affinity DataIC50: 6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397632BDBM397632(US9994547, Example 1 | (S)-N-(5-(4-cyano-3-((1-(di...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397777BDBM397777(US9994547, Example 146 | N-(5-(6-cyano-5-(((S)-1-(...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397637BDBM397637(US9994547, Example 6 | N-(5-(4-cyano-3-((1-(dimeth...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397750BDBM397750(US9994547, Example 119 | N-(5-(6-cyano-5-(((2S)-1-...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397639BDBM397639(US9994547, Example 8.0)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397677BDBM397677(US9994547, Example 46 | N-(5-(6-cyano-5-((1-((2,2-...)
Affinity DataIC50: 10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397643BDBM397643(US9994547, Example 12 | (S)-N-(5-(4-cyano-3-((1-(e...)
Affinity DataIC50: 10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397685BDBM397685(US9994547, Example 54 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397681BDBM397681(US9994547, Example 50 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397634BDBM397634(US9994547, Example 3.0)
Affinity DataIC50: 12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397720BDBM397720(US9994547, Example 89 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397712BDBM397712(US9994547, Example 81 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397713BDBM397713(US9994547, Example 82 | N-(5-(6-cyano-5-((2-((2,2-...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397660BDBM397660(US9994547, Example 29 | N-(5-(4-cyano-3-((1-((2-hy...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397727BDBM397727(US9994547, Example 96 | (S)-N-(5-(6-cyano-5-((2-ox...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397672BDBM397672(US9994547, Example 41 | N-(5-(6-cyano-5-((1-(methy...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397738BDBM397738(US9994547, Example 107 | (1R,2R)-N-(5-(6-cyano-5-(...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397781BDBM397781(US9994547, Example 150 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397703BDBM397703(US9994547, Example 72 | N-(5-(6-cyano-5-((2-((2,2-...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397745BDBM397745(US9994547, Example 114 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397650BDBM397650(US9994547, Example 19 | (S)-N-(5-(4-cyano-3-((1-((...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397678BDBM397678(US9994547, Example 47 | N-(5-(6-cyano-5-((1-((2-fl...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397743BDBM397743(US9994547, Example 112 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397722BDBM397722(US9994547, Example 91 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397770BDBM397770(US9994547, Example 139 | N-(5-(6-cyano-5-(((S)-1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397674BDBM397674(US9994547, Example 43 | N-(5-(6-cyano-5-((1-((cyan...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397739BDBM397739(US9994547, Example 108 | (1R,2S)-N-(5-(6-cyano-5-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397700BDBM397700(US9994547, Example 69 | N-(5-(6-cyano-5-(((2S)-1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397760BDBM397760(US9994547, Example 129 | US9994547, Example 135 | ...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397654BDBM397654(US9994547, Example 23 | (S)-N-(5-(4-cyano-3-((1-(d...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397687BDBM397687(US9994547, Example 56 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397744BDBM397744(US9994547, Example 113 | N-(5-(6-cyano-5-((2-((2S,...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397760BDBM397760(US9994547, Example 129 | US9994547, Example 135 | ...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397757BDBM397757(US9994547, Example 126 | N-(5-(4-cyano-3-((2-(meth...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397768BDBM397768(US9994547, Example 137 | (S)-N-(5-(4-cyano-3-((1-(...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397686BDBM397686(US9994547, Example 55 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397719BDBM397719(US9994547, Example 88 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397767BDBM397767(US9994547, Example 136 | (S)-N-(5-(4-cyano-3-((1-(...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397649BDBM397649(US9994547, Example 18 | N-(5-(4-cyano-3-((1-(dimet...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397676BDBM397676(US9994547, Example 45 | (R)-N-(5-(6-cyano-5-((2-(2...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397741BDBM397741(US9994547, Example 110 | N-(5-(6-cyano-5-((2-((2-h...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397695BDBM397695(US9994547, Example 64 | N-(5-(6-cyano-5-((2-oxo-2-...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 397780BDBM397780(US9994547, Example 149 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
US Patent

Displayed 1 to 50 (of 150 total ) | Next | Last >>
Jump to: